Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Rhea-AI Summary

Cadrenal Therapeutics (Nasdaq: CVKD), a biopharmaceutical company focused on anticoagulation therapy, will participate in the virtual Lytham Partners Fall 2025 Investor Conference on September 30, 2025.

The company's webcast presentation is scheduled for 3:30 p.m. ET and will be accessible through the conference website. Management will also be available for one-on-one meetings with investors throughout the event.

PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025.

Company Webcast

The webcast presentation will take place at 3:30 p.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/fall2025/ or directly at https://app.webinar.net/QG1g6kJWEM0. The webcast will also be available for replay following the event.

1x1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/fall2025invreg/.

About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy. Cadrenal’s lead investigational product is tecarfarin, a novel oral Vitamin K antagonist anticoagulant that is designed to address unmet needs in anticoagulation therapy. Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Although warfarin is widely used, extensive clinical and real-world data have shown it can have significant, serious side effects. With tecarfarin, Cadrenal aims to reduce the clinical complexities of managing Vitamin K antagonists, particularly where direct-acting oral anticoagulants (DOACs) remain inadequate or unproven.

Tecarfarin received Orphan Drug Designation (ODD) and fast-track designation for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage kidney disease and atrial fibrillation (ESKD+AFib). The Company also received ODD for the prevention of thromboembolism and thrombosis in patients with implanted mechanical circulatory support devices, including Left Ventricular Assist Devices (LVADs).

For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.

For more information, please contact:

Cadrenal Therapeutics:
Matthew Szot, CFO
press@cadrenal.com

Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com

FAQ

When is Cadrenal Therapeutics (CVKD) presenting at the Lytham Partners Fall 2025 Conference?

Cadrenal Therapeutics will present at 3:30 p.m. ET on Tuesday, September 30, 2025.

How can investors access CVKD's Lytham Partners conference presentation?

The presentation can be accessed through the conference website at lythampartners.com/fall2025/ or directly via webinar.net. A replay will be available after the event.

How can investors schedule one-on-one meetings with CVKD management?

Investors can arrange meetings by contacting Lytham Partners at 1x1@lythampartners.com or by registering at lythampartners.com/fall2025invreg/.

What is Cadrenal Therapeutics' main business focus?

Cadrenal Therapeutics is a biopharmaceutical company developing therapeutics to address gaps in anticoagulation therapy.